Welcome to the new Independent website. We hope you enjoy it and we value your feedback. Please contact us here.

Genentech rejects fresh Roche bid

Pharmaceuticals The Swiss giant Roche was rebuffed yesterday in its $42bn (£29bn) hostile bid to buy the shares it does not already own in the US biotech group Genentech.

The Genentech board advised shareholders to reject the $86.50-a-share bid for 44 per cent of the group, saying that the offer undervalued the company, which specialises in biotherapeutics.

The bid revises an offer of $89 a share, or $44bn, for the minority stake last year, which was also dismissed by Genentech directors as being inadequate. Genentech's bankers have indicated $112 a share as a fair price.